Lamivudine for the treatment of membranous glomerulopathy secondary to chronic hepatitis B infection

SI Gan MD FRCPC1, SM Devlin MD FRCPC1, NW Scott-Douglas MD FRCPC2, KW Burak MD FRCPC1,3

Membranous glomerulopathy is a well-recognized extrahepatic manifestation of chronic hepatitis B virus (HBV) infection. The authors report two cases of HBV-related nephrotic syndrome treated with lamivudine. A 46-year-old Chinese man had a hepatitis B e antigen seroconversion along with improvement in his nephrotic syndrome after lamivudine therapy. Two years after treatment was discontinued, a reactivation of HBV was successfully treated again with lamivudine. A 44-year-old Chinese woman, who was intolerant of interferon, was treated with lamivudine for 15 months without a virological response. However, two years after completing lamivudine, her nephrotic syndrome resolved. Implications for the treatment of HBV-related glomerulopathy and a review of the literature are presented.

Key Words: Antiviral therapy; Hepatitis B; Nephrotic syndrome

CASE PRESENTATIONS

Case 1
A 46-year-old Chinese man, known to be a chronic HBV carrier, presented in March 1999 with peripheral edema and abdominal swelling. His serum albumin was 13 g/L and a 24 h urine collection revealed 7.1 g/day of proteinuria. He was hypertensive and had hypercholesterolemia (total cholesterol 6.94 mmol/L), in keeping with nephrotic syndrome. The serum creatinine was normal. His alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were both noted to be elevated at two times the upper limit of normal (ULN). An abdominal ultrasound revealed a 2 cm hypoechoic nodule in the left lobe of the liver. An ultrasound-guided biopsy revealed cirrhosis with mild periportal inflammation. There was no evidence of hepatocellular carcinoma and the serum alpha fetoprotein was normal. The hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) were both positive. Hepatitis C serology was negative and other investigations including iron studies, ceruloplasmin, antinuclear antibody, immunoglobulins and alpha-1-antitrypsin were normal. Antineutrophil cytoplasmic antibodies, antinuclear antibody, antiglomerular basement membrane antibodies, syphils and HIV serology were all negative. The urine and serum protein electrophoresis only revealed findings consistent with nephrotic syndrome. Complement and cryoglobulin levels were not measured.

The patient was assessed by the nephrology service and, with negative investigations for other causes of nephrotic syndrome (malignancy, nonsteroidal anti-inflammatory drugs, systemic lupus, rheumatoid arthritis, sarcoidosis, Sjogren’s syndrome and schistosomiasis), the patient was thought to have MGN associated with HBV. A renal biopsy was not performed. The patient was started on lamivudine 100 mg/day in March 1999 along with enalapril 20 mg twice daily and diuretic therapy.

Two years after completing lamivudine, his nephrotic syndrome resolved. Implications for the treatment of HBV-related glomerulopathy are presented here with a review of the literature.

Correspondence: Dr Kelly W Burak, The University of Calgary Medical Clinic, Room G128 Health Sciences Centre, University of Calgary, 3330 Hospital Drive Northwest, Calgary, Alberta T2N 4N1. Telephone 403-210-9363, fax 403-210-9368, e-mail kwburak@ucalgary.ca

1Divisions of Gastroenterology and 2Nephrology, 3Liver Unit, Department of Medicine, University of Calgary, Calgary, Alberta
A 44-year-old Chinese woman, who was known to be a HBV carrier, presented in October 1998 with ankle edema. Subsequent investigations revealed nephrotic range proteinuria (16.6 g/day), microscopic hematuria with dysmorphic red blood cells, hypercholesterolemia (14.7 mmol/L) and significant hypoaalbuminemia (15 g/L). The serum creatinine was normal. A renal biopsy revealed changes consistent with membranous glomerulonephritis. The patient was started on diuretic therapy and pravastatin. Due to the patient’s low blood pressure, ACE inhibitors were never introduced. Further investigations revealed a normal ALT, a positive HBsAg and positive HBeAg. HBV DNA was present at a level of 5.1 pg/mL (Abbott assay, Abbott Laboratories, USA). Although she had a normal ALT level, a trial of antiviral therapy was undertaken in an attempt to improve the MGN. Interferon-alpha 2b, 10 million units three times weekly, was initiated but was discontinued after only five doses due to significant flu-like symptoms and fatigue. Lamivudine was then started at a dosage of 100 mg/day in March 1999. At this time, the serum ALT was normal and AST was 1.5 times the ULN. When lamivudine was initiated, a 24 h urine collection revealed 8.2 g of proteinuria per day, serum albumin was 13 g/L and total cholesterol was 11.1 mmol/L. After 12 months of lamivudine therapy, the patient remained HBeAg-positive with an HBV DNA level of 9.36 pg/mL (Hybrid Capture 2, Digene Corporation, USA). In June 2000, lamivudine was stopped after 15 months due to lack of virological response. The ALT remained normal, and the AST was still 1.5 times the ULN. Her albumin had increased to 18 g/L and nephrotic range proteinuria persisted (3.51 g/day). Over the next four years, with no further intervention, there was improvement of her nephrotic syndrome with normalization of her cholesterol and resolution of her peripheral edema. By April 2002, the degree of proteinuria had decreased to 1.82 g/day and by January 2003 it had further decreased to 0.37 g/day. More recently, in February 2004, she only had mild proteinuria (0.22 g/day). Despite the improvement in her nephrotic syndrome, she remains HBeAg-positive with detectable HBV DNA (greater than 200,000 copies/mL with the Cobas Amplicor PCR assay, Roche Diagnostics, USA) as of February 2005. Figure 1B illustrates the 24 h urine protein excretion in relationship to the use of interferon and lamivudine in this case.

DISCUSSION

HBV has long been known to be associated with a variety of glomerular diseases including membranous glomerulonephritis, membranoproliferative glomerulonephritis and mesangial proliferative glomerulonephritis (4-9). In addition, polyarteritis nodosa and immunoglobulin A nephropathy have also been associated with chronic HBV infection (10-13). First described in 1971 by Combes et al (4), MGN is the most commonly associated renal disorder, with epidemiological studies subsequently confirming its association with HBV. Serum positivity for HBsAg is seen in nearly all cases of MGN in Asia and Africa where there is a high prevalence of chronic HBV, but HBsAg is found in only 20% to 64% of MGN cases in countries that have low prevalence of chronic HBV (14-19). The disease can occur at any age but usually presents by the fourth decade. Both pediatric and adult series have been presented and a striking male predominance (in up to 80%) has been noted in both age groups (16,20).

By July 1999, the transaminases had normalized; there was marked improvement in the patient’s ascites and peripheral edema, allowing for discontinuation of the diuretics. HBeAg seroconversion was documented after five months of therapy (HBeAg-negative, anti-HBe-positive, HBV DNA-negative). Lamivudine was continued for a total of 12 months. At the end of 12 months, the albumin had increased to 30 g/L, cholesterol had decreased to 5.43 mmol/L and the level of proteinuria had decreased to 4.83 g/day. The patient was maintained on angiotensin-converting enzyme (ACE) inhibitors, and six months later the proteinuria improved to 1.41 g/day. Twelve months after stopping lamivudine, the serum albumin and cholesterol normalized, although the 24 h protein excretion was still elevated at 3.5 g/day.

In June 2002, the serum ALT rose to three times ULN. HBeAg remained negative, but HBV DNA was detected at a level of 9.4 pg/mL (Hybrid Capture 2, Digene Corporation, USA). The patient was asymptomatic and there was no evidence of decompensated liver disease. In July 2002, she was restarted on lamivudine 100 mg/day and within three months his ALT normalized and HBV DNA became undetectable. Lamivudine was discontinued after nine months but he remains on ACE inhibitors. He remains well with normal ALT, creatinine, albumin and cholesterol and only has mild proteinuria at 1.23 g/day as of February 2004. The timeline of lamivudine therapy in relation to the 24 h urine protein excretion in this case is shown in Figure 1A.
The etiology of HBV-related MGN remains unclear. Postulated to be a disease caused by immune complex deposition, early investigation focused on the three major hepatitis B antigens: surface, core and the 'e' antigen. There is debate about which of the three major antigens is responsible for the immune response. Initial studies used immunofluorescent staining to demonstrate the presence of all three antigens within glomerular deposits, but these results were not confirmed in other studies (4,5,21). A study by Maggiore et al (22) casts doubt on the validity of the immunoglobulin tests used in some studies. Furthermore, other studies have failed to demonstrate localization of preformed immune complexes in the glomerular subepithelium. Similarly, circulating immune complexes of hepatitis B antigens have been detected in some but not all studies (23-25). HBV DNA has also been isolated in the glomerulus and the proximal tubules of MGN patients, but the actual significance of this is unknown (26,27).

The natural history of HBV-related glomerulopathy has been collected from case series in both children and adults. Wong et al (20) retrospectively identified 18 pediatric cases in Hong Kong, in which 78% of children presented with nephrotic syndrome. Four patients presented with gross hematuria and proteinuria and three of these patients subsequently developed nephrotic syndrome some time later. Albumin and cholesterol levels were usually consistent with nephrotic syndrome. Five patients received no treatment, 11 received steroids and two received interferon. Within three years of diagnosis, 10 (59%) patients had complete and persistent remission. Of the untreated patients, only one achieved remission and the remaining patients had persistent proteinuria, chronic renal failure or end-stage renal failure (20).

Adult-onset HBV-related MGN may have a different natural history. In contrast to reports in children, a study (16) of 21 Hong Kong adult patients found that only one of the five patients treated with interferon experienced remission. Moreover, in that study, no untreated patients experienced spontaneous remission. The study also found a negative correlation between the extent of membrane deposits and the chance of complete remission.

The results of treatment of HBV-related MGN have been variable. Although there are controlled trials of corticosteroids in adults with idiopathic MGN, there have been no controlled studies in HBV-related MGN. Anecdotal and retrospective studies show no clear benefit of corticosteroids over symptomatic treatment with diuretics (28,29). Lai et al (28) studied eight adult patients with HBV-related MGN, of which seven of eight had nephrotic syndrome. A six-month course of corticosteroids was associated with partial resolution of nephrotic syndrome in three of seven patients. Two of seven historical controls treated with diuretics alone experienced a spontaneous remission. In another study by Wyseynska et al (29), immunosuppressive therapy did not alter the course of HBV-related MGN in children. Furthermore, short-term or prolonged steroid use may lead to an increase in viral replication and a subsequent worsening of hepatic function (28,30). There is a single case report (31) of liver transplantation resulting in resolution of HBV-related MGN in a 15-year-old girl.

Antiviral therapy for HBV-related MGN was first attempted as early as 1985 (32). Interferon and adenine arabinoside have both been used with variable success (33,34). Over 50 patients treated with interferon have been reported in the literature (20,34-42). In one case series (37) of 15 patients treated with interferon, eight patients had a virological response defined by loss of HBeAg and HBV DNA. Seven of these eight patients had improved renal function with decreased proteinuria. In contrast, none of the patients without seroconversion had an improvement in proteinuria and one patient went on to require dialysis (37). Lin (38) reported the only controlled trial of interferon in 1995. Forty patients were randomly assigned to treatment with interferon three times weekly for 12 months or supportive care. Of the 20 interferon-treated patients, 60% had HBeAg seroconversion, 40% had HBsAg seroconversion and all interferon-treated patients had resolution of proteinuria. Conversely, none of the untreated patients had HBeAg or HBsAg seroconversion and all continued to have significant proteinuria. The seroconversion rates in this study were much higher than those found in a meta-analysis of interferon trials (43), in which pooled HBeAg loss was seen in 33% and HBsAg seroconversion occurred in 7.8%. Although this observation is based on a small number of patients, this suggests that HBV patients with associated renal disease may be more responsive to interferon-based therapy.

Lamivudine is a pyrimidine nucleoside analogue that interrupts hepatitis B viral replication. The drug is well-tolerated and usually results in a significant reduction of HBV DNA levels. However, HBeAg seroconversion is achieved in only 16% to 18% of patients after one year of therapy (44). Extended durations of lamivudine therapy will improve seroconversion rates but comes at a cost of higher rates of YMDD mutants that confer resistance to lamivudine (44). To date, the use of lamivudine to specifically treat HBV-related MGN has mainly been reported in the pediatric literature (1,2). In one study (1), a six-year-old boy experienced remission of HBV-associated MGN after five months of lamivudine. In a second report (2), a five-year-old girl experienced remission after three months of lamivudine. In the single report (3) detailing the use of lamivudine in an adult, a 41-year-old man experienced remission of his HBV-associated MGN with the combined use of intravenous methylprednisolone and cyclophosphamide, rendering some doubt as to which therapy proved to be beneficial.

The exact impact of lamivudine in our two patients is unclear. The first patient had a prompt HBeAg seroconversion, which resulted in an improvement in his nephrotic syndrome, although he continues to have mild proteinuria. With the appearance of a precore mutant (HBeAg-negative, HBV DNA-positive), his nephrotic syndrome did not deteriorate and this recurrent viremia was brought under control with a second course of lamivudine. However, the patient has been on enalapril since his presentation. ACE inhibition has been shown to result in a significant reduction in proteinuria and preservation of renal function in non-diabetic patients with glomerular diseases (45). Therefore, we cannot exclude the possibility that the improvement in his nephrotic syndrome was related to the use of an ACE inhibitor and not due to the suppression of his HBV DNA by lamivudine.

The second patient had no virological response to 15 months of lamivudine therapy. In spite of ongoing HBV viremia, his nephrotic syndrome slowly resolved over the subsequent two years. It should be noted that this patient was not hypertensive and at no point were ACE inhibitors used. Slow improvement in nephrotic syndrome has also been noted in patients with a response to interferon (37), but our patient only received five doses of interferon. Spontaneous remission of HBV-associated
glomerulopathy in adults is apparently quite rare, although it did occur in two of seven historical controls treated with diuretics alone in the study by Lai et al (28). Although we cannot exclude the possibility that lamivudine may have influenced the natural history of her nephrotic syndrome, despite the lack of virological response, it appears more likely that she entered a spontaneous remission.

Regardless, in our experience, lamivudine was well-tolerated in both patients and improvement in the nephrotic syndrome was noted in both subjects. Therefore, lamivudine should be considered as an alternative to interferon for patients with HBV-related glomerulopathy. HBV patients with glomerulopathy may have a different natural history, with higher seroconversion rates when treated with interferon (38). Further studies are required to delineate the response rates and efficacy of lamivudine in this subgroup of HBV patients.

CONCLUSION

Lamivudine appears to be a potentially safe and effective means of treating adults with glomerular disease associated with HBV. Lamivudine should be considered a potential alternative to interferon for HBV patients with glomerulopathy who are intolerant of or unwilling to take interferon-based therapy. Whether a patient with HBV-related MGN will be more responsive to lamivudine, as was suggested with the use of interferon, deserves further study.

REFERENCES

37. Conjeevaram H, Hoofnagle J, Austin H, Park Y, Fried M, Di Bisceglie A. Long-term outcome of hepatitis B virus-related...


